Genelux Investor Presentation Deck
V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical
VACT
V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX
Biomedical, Inc. established to develop and test V2ACT.
Key Trial Takeaways
V2ACT Immunotherapy,
combines an oncolytic
immunotherapy and
adoptive cell therapy
ā
Induces an acute
inflammatory response in the
tumor and converts tumor
microenvironment from
immunosuppressive to
immunostimulatory;
Anticipated to enhance
effect of neoantigen specific
effector T cells
GENELUX
Vaccination increases the numbers of neoantigen-specific T cells in the body and
Olvi-Vec kills cancer cells and potentiates T cells by increasing cancer tissue
receptivity to adoptively transferred neoantigen-specific effector T cells.
Technology
Patients Dosed
Regulatory
TVI Adoptive Cell
Therapy
~ 130
Fast Track Designation / FDA
Grant
- glioblastoma
Olvi-Vec Oncolytic
Immunotherapy
~ 150
Phase 3 enrolling
- ovarian
Novel 10 modality: United States Patent No. 11,633,442, issued in April 2023
23View entire presentation